CSIR-Institute of Microbial Technology
Pradip Sen did his Ph.D. in immunobiology of visceral leishmaniasis with Dr. Syamal Roy from CSIR-Indian Institute of Chemical Biology (1994-2000), after which he went to Germany for post doctoral research in tumor immunology at Medical Faculty, Charite, Humboldt University. In 2001, Dr. Sen moved to University of North Carolina at Chapel Hill, USA, where he carried out another post doctoral research in Type-1 diabetes under Prof. Roland Tisch until he joined CSIR-Institute of Microbial Technology (CSIR-IMTECH) as Scientist in 2005. Since 2013, Dr. Pradip Sen is working as Principal Scientist at CSIR-IMTECH. Dr. Sen’s group has deciphered the mechanism by which antimony-resistant clinical isolates of Leishmania donovani attenuates the therapeutic efficacy of sodium antimony gluconate (SAG) by inhibiting dendritic cells, the key regulators of anti-leishmanial immune responses (PLoS Pathogens 6, e1000907, 2010). This was the first report that showed how host cells respond differentially to antimony-resistant and antimony-sensitive Leishmania parasites, which may influence the disease outcome. Currently, Dr. Sen’s group is exploring the role of a novel receptor in Leishmania donovani infection. In addition, Dr. Sen and his group are involved in developing monoclonal antibody-based biotherapeutics at CSIR-IMTECH.
3 publications that reflect my groups research efforts in the area of NTDs